ACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aurora Cannabis Inc (ACB) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The company faces significant challenges, including weak revenue growth, consistent net losses, and limited presence in the U.S. market. Despite minor positive technical indicators, the overall sentiment, financial performance, and lack of strong positive catalysts make this stock unsuitable for the given investment profile.
The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 65.436, and moving averages are converging, showing no strong directional bias. Key resistance levels are at 3.86 and 3.996, with support at 3.638 and 3.416. However, the stock has a 60% chance of declining in the short term (-2.27% in the next day, -3.8% in the next week).
The company's gross margin increased by 69.91% YoY in Q3 2026, indicating some operational improvement. Analysts maintain a Buy rating with a price target of C$9, citing Aurora's strong position in international markets like Germany, Poland, Australia, and the UK.
Recent news sentiment is overwhelmingly negative.
In Q3 2026, revenue increased by 6.79% YoY to $94.19 million. However, net income dropped by 93.63% YoY to $1.82 million, and EPS fell by 94.23% YoY to $0.03. Gross margin improved by 69.91% YoY to 5.93%, but overall financial performance remains weak.
Canaccord maintains a Buy rating but lowered the price target from C$10 to C$9, reflecting cautious optimism. Analysts highlight Aurora's strong international presence but acknowledge challenges in the U.S. market and weak financial performance.
